From FDA labels and ClinicalTrials.gov

Do GLP-1s help during menopause?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists menopause as an approved use, so prescribing one for it would be off-label. Look-back study (Semaglutide): In postmenopausal women on semaglutide, those also on hormone therapy had lost 16% of their weight at 12 months, and those not on it 12%. A small study that shows a link, not a cause. It measured weight, not menopause symptoms. Menopause, 2024 (pubmed.ncbi.nlm.nih.gov/38446869). ClinicalTrials.gov lists 14 trials of these medicines on it: 0 with posted results and 4 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 18, 2026.

Published results

What the largest trials on menopause found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

Look-back study

Semaglutide · 106 people · Mixed · Observational study

In postmenopausal women on semaglutide, those also on hormone therapy had lost 16% of their weight at 12 months, and those not on it 12%. A small study that shows a link, not a cause. It measured weight, not menopause symptoms.

Menopause, 2024 (pubmed.ncbi.nlm.nih.gov/38446869)

The registry

Trials on menopause, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide701
Tirzepatide202
Exenatide100
Liraglutide100
MariTide100
Retatrutide100
Survodutide101
Recruiting now

Trials on menopause taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight (clinicaltrials.gov/study/NCT07850050)SurvodutidePhase 3Jul 26, 2028
Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (clinicaltrials.gov/study/NCT06975111)SemaglutidePhase 2/3Oct 1, 2030
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity (clinicaltrials.gov/study/NCT07218445)TirzepatidePhase 4Sep 18, 2027
Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors (clinicaltrials.gov/study/NCT07257484)TirzepatidePhase 4Feb 25, 2028
Updated automatically

What changed in trials on menopause

  • TrialSurvodutide study now recruiting (was not yet recruiting): SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight (clinicaltrials.gov/study/NCT07850050)
  • TrialNew Survodutide study registered: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight (clinicaltrials.gov/study/NCT07850050)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and menopause: common questions

What did the largest trial on menopause find?

Look-back study (Semaglutide, 106 people): In postmenopausal women on semaglutide, those also on hormone therapy had lost 16% of their weight at 12 months, and those not on it 12%. A small study that shows a link, not a cause. It measured weight, not menopause symptoms.

Is any GLP-1 FDA approved for menopause?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for menopause?

Semaglutide, with 7 registered trials on it, then Tirzepatide with 2. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for menopause?

4 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.